1. Optimizing Frontline Care for Older Patients With Multiple Myeloma

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Multiple Myeloma Diagnosis by Age

4. Individual Approach to Patients

5. Assessing Patients for Fitness

6. IMWG Geriatric Assessment

8. Geriatric Assessment in Hematology

11. Induction Therapy

13. Prevention of Thromboembolism IMWG Recommendations

14. Antiviral Prophylaxis

15. Managing Infections

16. Peripheral Neuropathy

17. Expert Opinion: Oral Therapies

18. ALCYONE Study

19. Underutilization of ASCT

20. Patients With MM Are Heterogeneous

22. Bone-Modifying Agents

23. Case 1: Jim

24. Case 1, Jim: Faculty Recommendations

25. What If Jim Had High-Risk MM?

26. Case 2: Kathy

27. Case 2, Kathy: Faculty Recommendations

28. Case 3: Gary

29. Case 3, Gary: Faculty Recommendations

30. Key Takeaways

31. Abbreviations

32. Abbreviations (cont)